Wall Street analysts forecast that Axovant Gene Therapies Ltd (NASDAQ:AXGT) will announce earnings of ($1.15) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Axovant Gene Therapies’ earnings. The highest EPS estimate is ($0.76) and the lowest is ($1.39). Axovant Gene Therapies reported earnings per share of ($2.24) during the same quarter last year, which would suggest a positive year over year growth rate of 48.7%. The firm is scheduled to report its next earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Axovant Gene Therapies will report full-year earnings of ($4.25) per share for the current year, with EPS estimates ranging from ($5.59) to ($3.47). For the next financial year, analysts forecast that the firm will post earnings of ($3.32) per share, with EPS estimates ranging from ($4.35) to ($2.89). Zacks’ EPS averages are an average based on a survey of analysts that cover Axovant Gene Therapies.
Axovant Gene Therapies (NASDAQ:AXGT) last posted its quarterly earnings results on Friday, August 9th. The company reported ($1.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.34) by $0.11.
Shares of NASDAQ:AXGT traded up $0.04 during midday trading on Friday, reaching $6.72. 11,202 shares of the company were exchanged, compared to its average volume of 176,729. The company has a current ratio of 1.70, a quick ratio of 1.70 and a debt-to-equity ratio of 0.60. The company’s fifty day moving average is $6.76. Axovant Gene Therapies has a one year low of $3.81 and a one year high of $20.80. The firm has a market capitalization of $153.31 million, a PE ratio of -0.84 and a beta of 1.29.
In other news, CEO Pavan Cheruvu bought 7,500 shares of Axovant Gene Therapies stock in a transaction dated Friday, June 14th. The shares were acquired at an average price of $5.21 per share, with a total value of $39,075.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.60% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Primecap Management Co. CA acquired a new stake in shares of Axovant Gene Therapies in the first quarter valued at approximately $1,400,000. Marshall Wace LLP acquired a new stake in shares of Axovant Gene Therapies in the first quarter valued at approximately $272,000. Sphera Funds Management LTD. acquired a new stake in shares of Axovant Gene Therapies in the first quarter valued at approximately $6,794,000. BlackRock Inc. acquired a new stake in shares of Axovant Gene Therapies in the second quarter valued at approximately $1,482,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Axovant Gene Therapies by 955.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the company’s stock valued at $27,000 after acquiring an additional 3,821 shares during the period.
About Axovant Gene Therapies
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Featured Story: Put Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.